Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (1-10 of 335) with videos related to

Pageof 34
Sort By:
World Journal of Urology|May 23, 2018
A new prognostic model for localized renal cell carcinomaSebastiano Buti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Does the cetuximab plus paclitaxel combination deserve to be studied in a phase III trial?Sebastiano Buti
Therapeutic Advances in Medical Oncology|October 5, 2017
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potentialMelissa Bersanelli, Sebastiano Buti
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2022
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?Giulia Mazzaschi, Sebastiano Buti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?Sebastiano Buti, Melissa Bersanelli
Future Oncology (London, England)|February 7, 2024
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice?Michele Maffezzoli, Sebastiano Buti
Future Oncology (London, England)|May 12, 2016
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trialsSebastiano Buti, Melissa Bersanelli
World Journal of Clinical Oncology|March 2, 2017
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axisMelissa Bersanelli, Sebastiano Buti
The Lancet. Oncology|October 21, 2015
Combination therapy in kidney cancer: the next revolution?Sebastiano Buti, Melissa Bersanelli
Acta Bio-Medica : Atenei Parmensis|September 21, 2016
Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?Melissa Bersanelli, Sebastiano Buti
Pageof 34

Showing results (1-10 of 335) with videos related to

Sort By:
Pageof 34
World Journal of Urology|May 23, 2018
A new prognostic model for localized renal cell carcinomaSebastiano Buti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Does the cetuximab plus paclitaxel combination deserve to be studied in a phase III trial?Sebastiano Buti
Therapeutic Advances in Medical Oncology|October 5, 2017
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potentialMelissa Bersanelli, Sebastiano Buti
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2022
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?Giulia Mazzaschi, Sebastiano Buti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?Sebastiano Buti, Melissa Bersanelli
Future Oncology (London, England)|February 7, 2024
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice?Michele Maffezzoli, Sebastiano Buti
Future Oncology (London, England)|May 12, 2016
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trialsSebastiano Buti, Melissa Bersanelli
World Journal of Clinical Oncology|March 2, 2017
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axisMelissa Bersanelli, Sebastiano Buti
The Lancet. Oncology|October 21, 2015
Combination therapy in kidney cancer: the next revolution?Sebastiano Buti, Melissa Bersanelli
Acta Bio-Medica : Atenei Parmensis|September 21, 2016
Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?Melissa Bersanelli, Sebastiano Buti
Pageof 34